Back to Search
Start Over
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO)
- Source :
- Frontiers in Cardiovascular Medicine, Vol 7 (2020), Frontiers in Cardiovascular Medicine, 7:585866. Frontiers Media S.A., Frontiers in Cardiovascular Medicine
- Publication Year :
- 2020
- Publisher :
- Frontiers Media S.A., 2020.
-
Abstract
- Background: Italy has one of the world’s oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-19. Whether hypertensionmedicationsmay increase the risk for death in older COVID 19 inpatients at the highest risk for the disease is currently unknown. Methods: Data from 5,625 COVID-19 inpatients were manually extracted from medical charts from 61 hospitals across Italy. From the initial 5,625 patients, 3,179 were included in the study as they were either discharged or deceased at the time of the data analysis. Primary outcome was inpatient death or recovery. Mixed effects logistic regression models were adjusted for sex, age, and number of comorbidities, with a random effect for site. Results: A large proportion of participating inpatients were ≥65 years old (58%), male (68%), non-smokers (93%) with comorbidities (66%). Each additional comorbidity increased the risk of death by 35% [adjOR = 1.35 (1.2, 1.5) p < 0.001]. Use of ACE inhibitors, ARBs, beta-blockers or Ca-antagonists was not associated with significantly increased risk of death. There was a marginal negative association between ARB use and death, and a marginal positive association between diuretic use and death. Conclusions: This Italian nationwide observational study of COVID-19 inpatients, the majority of which ≥65 years old, indicates that there is a linear direct relationship between the number of comorbidities and the risk of death. Among CVDs, hypertension and pre-existing cardiomyopathy were significantly associated with risk of death. The use of hypertension medications reported to be safe in younger cohorts, do not contribute significantly to increased COVID-19 related deaths in an older population that suffered one of the highest death tolls worldwide.
- Subjects :
- 0301 basic medicine
COVID-19, comorbidities, ACE inhibitors, mortality, cohort study
medicine.medical_specialty
comorbiditie
lcsh:Diseases of the circulatory (Cardiovascular) system
ACE inhibitors
Coronavirus disease 2019 (COVID-19)
COVID-19
cohort study
comorbidities
mortality
Cardiomyopathy
Socio-culturale
Disease
030204 cardiovascular system & hematology
Cardiovascular Medicine
Logistic regression
Older population
Comorbidities
03 medical and health sciences
0302 clinical medicine
SDG 3 - Good Health and Well-being
Internal medicine
ACE inhibitor
medicine
Mortality
Original Research
business.industry
Cohort study
medicine.disease
Comorbidity
030104 developmental biology
lcsh:RC666-701
Observational study
Erratum
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- Language :
- English
- ISSN :
- 2297055X
- Database :
- OpenAIRE
- Journal :
- Frontiers in Cardiovascular Medicine, Vol 7 (2020), Frontiers in Cardiovascular Medicine, 7:585866. Frontiers Media S.A., Frontiers in Cardiovascular Medicine
- Accession number :
- edsair.doi.dedup.....a81db8c97344d168b2aa1607743af63a